Plasticity and mTOR

Towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders

Tanjala Gipson, Michael V. Johnston

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective. To review the recent literature on the clinical features, genetic mutations, neurobiology associated with dysregulation of mTOR (mammalian target of rapamycin), and clinical trials for tuberous sclerosis complex (TSC), neurofibromatosis-1 (NF1) and fragile X syndrome (FXS), and phosphatase and tensin homolog hamartoma syndromes (PTHS), which are neurogenetic disorders associated with abnormalities in synaptic plasticity and mTOR signaling. Methods. Pubmed and Clinicaltrials.gov were searched using specific search strategies. Results/Conclusions. Although traditionally thought of as irreversible disorders, significant scientific progress has been made in both humans and preclinical models to understand how pathologic features of these neurogenetic disorders can be reduced or reversed. This paper revealed significant similarities among the conditions. Not only do they share features of impaired synaptic plasticity and dysregulation of mTOR, but they also share clinical featuresautism, intellectual disability, cutaneous lesions, and tumors. Although scientific advances towards discovery of effective treatment in some disorders have outpaced others, progress in understanding the signaling pathways that connect the entire group indicates that the lesser known disorders will become treatable as well.

Original languageEnglish (US)
Article number486402
JournalNeural Plasticity
Volume2012
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Neuronal Plasticity
Sirolimus
Fragile X Syndrome
Tuberous Sclerosis
Neurofibromatosis 1
Hamartoma
Neurobiology
Phosphoric Monoester Hydrolases
PubMed
Intellectual Disability
Clinical Trials
Skin
Mutation
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Plasticity and mTOR : Towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders. / Gipson, Tanjala; Johnston, Michael V.

In: Neural Plasticity, Vol. 2012, 486402, 01.01.2012.

Research output: Contribution to journalArticle

@article{5648aeefb96b4d89915272ef83ae411c,
title = "Plasticity and mTOR: Towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders",
abstract = "Objective. To review the recent literature on the clinical features, genetic mutations, neurobiology associated with dysregulation of mTOR (mammalian target of rapamycin), and clinical trials for tuberous sclerosis complex (TSC), neurofibromatosis-1 (NF1) and fragile X syndrome (FXS), and phosphatase and tensin homolog hamartoma syndromes (PTHS), which are neurogenetic disorders associated with abnormalities in synaptic plasticity and mTOR signaling. Methods. Pubmed and Clinicaltrials.gov were searched using specific search strategies. Results/Conclusions. Although traditionally thought of as irreversible disorders, significant scientific progress has been made in both humans and preclinical models to understand how pathologic features of these neurogenetic disorders can be reduced or reversed. This paper revealed significant similarities among the conditions. Not only do they share features of impaired synaptic plasticity and dysregulation of mTOR, but they also share clinical featuresautism, intellectual disability, cutaneous lesions, and tumors. Although scientific advances towards discovery of effective treatment in some disorders have outpaced others, progress in understanding the signaling pathways that connect the entire group indicates that the lesser known disorders will become treatable as well.",
author = "Tanjala Gipson and Johnston, {Michael V.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1155/2012/486402",
language = "English (US)",
volume = "2012",
journal = "Neural Plasticity",
issn = "2090-5904",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Plasticity and mTOR

T2 - Towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders

AU - Gipson, Tanjala

AU - Johnston, Michael V.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Objective. To review the recent literature on the clinical features, genetic mutations, neurobiology associated with dysregulation of mTOR (mammalian target of rapamycin), and clinical trials for tuberous sclerosis complex (TSC), neurofibromatosis-1 (NF1) and fragile X syndrome (FXS), and phosphatase and tensin homolog hamartoma syndromes (PTHS), which are neurogenetic disorders associated with abnormalities in synaptic plasticity and mTOR signaling. Methods. Pubmed and Clinicaltrials.gov were searched using specific search strategies. Results/Conclusions. Although traditionally thought of as irreversible disorders, significant scientific progress has been made in both humans and preclinical models to understand how pathologic features of these neurogenetic disorders can be reduced or reversed. This paper revealed significant similarities among the conditions. Not only do they share features of impaired synaptic plasticity and dysregulation of mTOR, but they also share clinical featuresautism, intellectual disability, cutaneous lesions, and tumors. Although scientific advances towards discovery of effective treatment in some disorders have outpaced others, progress in understanding the signaling pathways that connect the entire group indicates that the lesser known disorders will become treatable as well.

AB - Objective. To review the recent literature on the clinical features, genetic mutations, neurobiology associated with dysregulation of mTOR (mammalian target of rapamycin), and clinical trials for tuberous sclerosis complex (TSC), neurofibromatosis-1 (NF1) and fragile X syndrome (FXS), and phosphatase and tensin homolog hamartoma syndromes (PTHS), which are neurogenetic disorders associated with abnormalities in synaptic plasticity and mTOR signaling. Methods. Pubmed and Clinicaltrials.gov were searched using specific search strategies. Results/Conclusions. Although traditionally thought of as irreversible disorders, significant scientific progress has been made in both humans and preclinical models to understand how pathologic features of these neurogenetic disorders can be reduced or reversed. This paper revealed significant similarities among the conditions. Not only do they share features of impaired synaptic plasticity and dysregulation of mTOR, but they also share clinical featuresautism, intellectual disability, cutaneous lesions, and tumors. Although scientific advances towards discovery of effective treatment in some disorders have outpaced others, progress in understanding the signaling pathways that connect the entire group indicates that the lesser known disorders will become treatable as well.

UR - http://www.scopus.com/inward/record.url?scp=84861049888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861049888&partnerID=8YFLogxK

U2 - 10.1155/2012/486402

DO - 10.1155/2012/486402

M3 - Article

VL - 2012

JO - Neural Plasticity

JF - Neural Plasticity

SN - 2090-5904

M1 - 486402

ER -